Researchers in Germany have found a way to detect a biomarker for bladder cancer (called AHNAK2) for the first time. The presence of AHNAK2 indicates non-invasive bladder cancer, as opposed to cystitis, or bladder infection.
The new method is highly sensitive for low- and high-grade bladder cancer, the researchers report in The American Journal of Pathology, and could help detect cancer recurrence or persistence, which is important because:
- Treatment for bladder cancer can cause inflammation that must be differentiated from cancer itself
- Misdiagnosis could lead to aggressive disease or unnecessary treatment
According to the American Cancer Society, about 80,470 new cases of bladder cancer will be diagnosed in the United States in 2019 and approximately 17,670 people will die from bladder cancer.
Sourced from: The American Journal of Pathology